Bicara Therapeutics Common Net Income
| BCAX Stock | 13.99 0.81 5.47% |
As of the 12th of February 2026, Bicara Therapeutics shows the mean deviation of 2.85, and Risk Adjusted Performance of 0.0271. Bicara Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Bicara Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bicara Therapeutics' valuation are provided below:We have found one hundred one available fundamental signals for Bicara Therapeutics Common, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Bicara Therapeutics Common prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 971.2 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -61.2 M | -64.3 M | |
| Net Loss | -61.2 M | -64.3 M | |
| Net Loss | (1.44) | (1.51) | |
| Net Income Per E B T | 0.90 | 0.80 |
Bicara | Net Income | Build AI portfolio with Bicara Stock |
The evolution of Net Income for Bicara Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bicara Therapeutics compares to historical norms and industry peers.
Latest Bicara Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Bicara Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bicara Therapeutics financial statement analysis. It represents the amount of money remaining after all of Bicara Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bicara Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (68 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Bicara Net Income Regression Statistics
| Arithmetic Mean | (43,377,399) | |
| Coefficient Of Variation | (24.66) | |
| Mean Deviation | 8,461,315 | |
| Median | (37,845,000) | |
| Standard Deviation | 10,698,669 | |
| Sample Variance | 114.5T | |
| Range | 30.1M | |
| R-Value | (0.72) | |
| Mean Square Error | 58T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | (1,535,137) | |
| Total Sum of Squares | 1831.4T |
Bicara Net Income History
Other Fundumenentals of Bicara Therapeutics
Bicara Therapeutics Net Income component correlations
Bicara Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bicara Therapeutics is extremely important. It helps to project a fair market value of Bicara Stock properly, considering its historical fundamentals such as Net Income. Since Bicara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bicara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bicara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicara Therapeutics. Projected growth potential of Bicara fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bicara Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Bicara Therapeutics is measured differently than its book value, which is the value of Bicara that is recorded on the company's balance sheet. Investors also form their own opinion of Bicara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicara Therapeutics' market value can be influenced by many factors that don't directly affect Bicara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bicara Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bicara Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bicara Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Bicara Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bicara Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bicara Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Bicara Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Bicara Therapeutics Common or generate 0.0% return on investment in Bicara Therapeutics over 90 days. Bicara Therapeutics is related to or competes with Kura Oncology, Septerna Common, Eyepoint Pharmaceuticals, ProKidney Corp, Prime Medicine, Tango Therapeutics, and Phathom Pharmaceuticals. Bicara Therapeutics is entity of United States More
Bicara Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bicara Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bicara Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.15 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 19.25 | |||
| Value At Risk | (4.85) | |||
| Potential Upside | 6.05 |
Bicara Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bicara Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bicara Therapeutics' standard deviation. In reality, there are many statistical measures that can use Bicara Therapeutics historical prices to predict the future Bicara Therapeutics' volatility.| Risk Adjusted Performance | 0.0271 | |||
| Jensen Alpha | 0.0319 | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.1567 |
Bicara Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0271 | |||
| Market Risk Adjusted Performance | 0.1667 | |||
| Mean Deviation | 2.85 | |||
| Semi Deviation | 3.09 | |||
| Downside Deviation | 3.15 | |||
| Coefficient Of Variation | 4111.81 | |||
| Standard Deviation | 3.66 | |||
| Variance | 13.4 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0319 | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.1567 | |||
| Maximum Drawdown | 19.25 | |||
| Value At Risk | (4.85) | |||
| Potential Upside | 6.05 | |||
| Downside Variance | 9.93 | |||
| Semi Variance | 9.57 | |||
| Expected Short fall | (3.45) | |||
| Skewness | 0.4891 | |||
| Kurtosis | 0.6777 |
Bicara Therapeutics Backtested Returns
At this stage we consider Bicara Stock to be not too volatile. Bicara Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0183, which signifies that the company had a 0.0183 % return per unit of standard deviation over the last 3 months. We have found twenty-six technical indicators for Bicara Therapeutics Common, which you can use to evaluate the volatility of the firm. Please confirm Bicara Therapeutics' mean deviation of 2.85, and Risk Adjusted Performance of 0.0271 to double-check if the risk estimate we provide is consistent with the expected return of 0.0665%. Bicara Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bicara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicara Therapeutics is expected to be smaller as well. Bicara Therapeutics right now shows a risk of 3.64%. Please confirm Bicara Therapeutics treynor ratio, and the relationship between the coefficient of variation and semi variance , to decide if Bicara Therapeutics will be following its price patterns.
Auto-correlation | 0.37 |
Below average predictability
Bicara Therapeutics Common has below average predictability. Overlapping area represents the amount of predictability between Bicara Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bicara Therapeutics price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Bicara Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | -0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.57 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bicara Therapeutics Common reported net income of (68 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
Bicara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bicara Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bicara Therapeutics could also be used in its relative valuation, which is a method of valuing Bicara Therapeutics by comparing valuation metrics of similar companies.Bicara Therapeutics is currently under evaluation in net income category among its peers.
Bicara Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bicara Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bicara Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Bicara Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 531.89 M | ||||
| Shares Outstanding | 54.78 M | ||||
| Shares Owned By Insiders | 12.16 % | ||||
| Shares Owned By Institutions | 92.48 % | ||||
| Number Of Shares Shorted | 8.9 M | ||||
| Price To Book | 2.04 X | ||||
| EBITDA | (82.33 M) | ||||
| Net Income | (68 M) | ||||
| Total Debt | 738 K | ||||
| Book Value Per Share | 7.38 X | ||||
| Cash Flow From Operations | (74.75 M) | ||||
| Short Ratio | 20.17 X | ||||
| Earnings Per Share | 5.38 X | ||||
| Target Price | 30.8 | ||||
| Number Of Employees | 55 | ||||
| Market Capitalization | 820.09 M | ||||
| Total Asset | 569.2 M | ||||
| Retained Earnings | (221.02 M) | ||||
| Working Capital | 484.54 M | ||||
| Net Asset | 569.2 M |
About Bicara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bicara Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicara Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.